(Q46188099)

20 December 2017

title

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics (English)

1 reference

20 December 2017

1 reference

7

Arif B Ekici

1 reference

20 December 2017

1

Peter A Fasching

1 reference

20 December 2017

10

Matthias W Beckmann

1 reference

20 December 2017

9

Arndt Hartmann

1 reference

20 December 2017

Lothar Haeberle

3

object named as

Lothar Haeberle

1 reference

20 December 2017

author name string

Sebastian Weihbrecht

2

1 reference

20 December 2017

Armen Gasparyan

4

1 reference

20 December 2017

Ivonne E Villalobos

5

1 reference

20 December 2017

Yanling Ma

6

1 reference

20 December 2017

David L Wachter

8

1 reference

20 December 2017

Dennis J Slamon

11

1 reference

20 December 2017

Michael F Press

12

1 reference

20 December 2017

language of work or name

English

0 references

publication date

29 March 2014

1 reference

20 December 2017

Breast Cancer Research and Treatment

published in

1 reference

20 December 2017

volume

145

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

193-203

1 reference

20 December 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Advances in Breast Cancer - Looking Back over the Year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Breast Cancer 2012 - New Aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

The role of genetic breast cancer susceptibility variants as prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Fixation time does not affect expression of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Fixation time does not affect expression of HER2/neu: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

High order chromatin architecture shapes the landscape of chromosomal alterations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2922-X

10.1007/S10549-014-2922-X

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017